Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBio

Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBio

China's ApolloBio increased its upfront payment to obtain Greater China rights to Inovio's HPV immunotherapy.

Inovio and China’s ApolloBio have agreed to tweak their exclusive licensing deal formed about a year ago over Inovio’s DNA immunotherapy VGX-3100, which is designed to treat precancers caused by HPV.